Sify announces first ever dividend on equity shares of the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sify announces first ever dividend on equity shares of the company

MILPITAS, CA, CALIF., June 10, 2014 (GLOBE NEWSWIRE) -- Sify Technologies Limited (Nasdaq: SIFY ), a leader in Managed Enterprise, Network, IT and Software services in India with global delivery capabilities, today announced its first ever dividend payout to all holders of Equity and American Depository Shares of the company.

Further to the adoption of the financial statements for FY 2013-14 under India GAAP, the Board of Directors has recommended a dividend of 10% on the paid up capital of the equity shares and ADR holders for the year 2013-14. This is subject to the approval of the shareholders to be sought at the Annual General Meeting scheduled on July 28, 2014.

Dividend will be paid to those shareholders whose names appear in the Register of Members of the company (for India) and Citibank Depository Register (for ADRs) on the Record Date, June 20, 2014. The payment will be disbursed on July 30, 2014.

It may be recalled that Sify had in April announced their unaudited results under IFRS for the financial year ended March 2014.

About Sify Technologies

Sify is among the largest integrated ICT Solutions and Services companies in India, offering end-to-end solutions with a comprehensive range of products delivered over a common telecom data network infrastructure reaching more than 1300 cities and towns in India. This telecom network today connects 36 Data Centres across India including Sify's 5 Tier III Data Centres across the cities of Chennai, Mumbai, Delhi and Bengaluru.

A significant part of the company's revenue is derived from Enterprise Services, comprised of Telecom services, Data Center services, Cloud and Managed services, Applications Integration services and Technology Integration services. Sify also provides services that cater to the burgeoning demands of the SMB community, much of it on its Cloud services platform.

Sify is ISO 9001:2008 certified for Enterprise Sales, Provisioning, support and customer relationship management of ICT solutions and services including VPN, Network, Voice, Data Centre hosting, Integration services, security services and managed services. Sify has been certified in ISO / IEC 20000 - 1:2011 and ISO/IEC 27001:2005 certified for Internet Data Center operations. Sify has been certified in SSAE16 SOC2 Type II for Cloud Infrastructure. Sify has licenses to operate NLD (National Long Distance) and ILD (International Long Distance) services and offers VoIP backhaul for international carriers. With the Sify Cable landing station and partnerships with submarine cable companies globally, Sify is present in almost all the spheres of the ICT eco system.
The company has an expanding base of Managed Services customers, both in India and overseas, and is India's first enterprise managed services provider to launch a Security Operations Center (SOC) to deliver managed security services. The software team develops applications and offers services to improve business efficiencies of its current and prospective client bases. Sify also offers services in the specialized domains of eLearning, both in India and globally.
For more information about Sify, visit www.sifycorp.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Sify undertakes no duty to update any forward-looking statements.
For a discussion of the risks associated with Sify's business, please see the discussion under the caption "Risk Factors" in the company's Annual Report on Form 20-F for the year ended March 31, 2013, which has been filed with the United States Securities and Exchange Commission and is available by accessing the database maintained by the SEC at www.sec.gov , and Sify's other reports filed with the SEC.

For further information, please contact:
Sify Technologies Limited
Mr. Praveen Krishna
Investor Relations & Public Relations
+91 44 22540777 (ext.2055)
praveen.krishna@sifycorp.com
Grayling Investor Relations
Ms. Trúc Nguyen (ext. 418)
+1-646-284-9400
truc.nguyen@grayling.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

Coke Florida's Commitment to Coastal Cleanliness Shines Bright

Updated Category News Views 141

Coke Florida's Volunteer Contributions for Coastal Cleanup Day Coca-Cola Beverages Florida, LLC (Coke Florida) was excited to take part in the worldwide celebration of International Coastal Cleanup (ICC) Day. This initiative, which focuses on sustainability and building community resilience, encouraged employees across the company's vast market to unite for a meaningful...

Continue Reading
LifeMD's Growth Momentum: Strong Earnings and Legal Support

Updated Category News Views 96

LifeMD Maintains Buy Rating Amid Positive Developments BTIG has reaffirmed its support for LifeMD Inc (NASDAQ: LFMD) by maintaining a Buy rating and a price target of $12.00 for the company’s stock. This endorsement comes at a pivotal time as the company experiences recent developments in the ongoing legal proceedings regarding tirzepatide, a drug used for treating type...

Continue Reading
Innovative Electric Heating Pad Adapter Set to Transform Comfort

Updated Category News Views 120

Innovative Heating Pad Adapter for Vehicles Inventors continuously strive to enhance daily experiences, and one such innovation is set to revolutionize comfort during travel. An inventor, inspired by the need for warmth while driving, developed the RIDE ALONG PRONG PLUG IN, a unique electric heating pad adapter accessible through a vehicle's cigarette lighter socket....

Continue Reading
Hang Feng Capital's Innovations Shine at Asia’s FinTech Hub

Updated Category News Views 158

Hang Feng Capital Excels at Hong Kong FinTech Week Recently, a remarkable event unfolded in the heart of Asia's financial landscape as Hang Feng Capital showcased its innovations during Hong Kong FinTech Week. Co-hosted by the local government and InvestHK, this pivotal event brought together over 700 exhibitors, 800 speakers, and an impressive crowd of 37,000 attendees...

Continue Reading
Autoliv Inc. Adjusts Revenue Forecast Amid Changing Market

Updated Category News Views 60

Autoliv Inc. got slapped with a serious reality check back in 2024 when JPMorgan revised its price target to $119, up just a hair from $117. You could feel the desks twitching as analysts dove into the automotive safety systems market, flagging Autoliv’s shaky standing amidst some forecasted storms brewing on the horizon. Global light vehicle production was supposed to...

Continue Reading